Biomarin Pharmaceutical Inc BMRN:NASDAQ

Last Price$90.74NASDAQ Previous Close - Last Trade as of 4:00PM ET 3/24/23
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$88.25 (14)
Ask (Size)$93.31 (4)
Day Low / HighN/A - N/A
Volume772.2 K

View Biotechnology IndustryPeer Comparison as of 03/24/2023


Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $90.74
Change: +0.63 (0.70%)
Volume: 772.2 K
4:00PM ET 3/24/2023

Bio-Techne Corp ( NASDAQ )

Price: $72.54
Change: +0.62 (0.86%)
Volume: 825.4 K
4:00PM ET 3/24/2023

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Halozyme Therapeutics Inc ( NASDAQ )

Price: $34.49
Change: +0.81 (2.40%)
Volume: 1.6 M
4:00PM ET 3/24/2023

Elanco Animal Health Inc ( NYSE )

Price: $8.82
Change: +0.03 (0.34%)
Volume: 12.8 M
7:00PM ET 3/24/2023

Read more news Recent News

Bernstein Initiates BioMarin Pharmaceutical at Underperform With $81 Price Target
7:34AM ET 3/21/2023 MT Newswires

BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $74 to $200, according to analysts polled by Capital IQ....

Credit Suisse Lowers BioMarin Pharmaceutical's Price Target to $122 From $127, Maintains Outperform Rating
9:19AM ET 3/20/2023 MT Newswires

BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $74 to $200, according to analysts polled by Capital IQ....

Insider Sell: Biomarin Pharmaceutical
12:37AM ET 3/15/2023 MT Newswires

Jean Jacques Bienaime, Director, Chief Executive Officer, on March 10, 2023, sold 23,000 shares in Biomarin Pharmaceutical (BMRN) for $2,107,800. Following...

BMO Capital Cuts Price Target on BioMarin Pharmaceutical to $102 From $107, Maintains Market Perform Rating
9:52AM ET 3/07/2023 MT Newswires

BioMarin Pharmaceutical (BMRN) has an average outperform rating and price target range of $74 to $200, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionBioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA. View company web site for more details
Address770 Lindaro Street
San Rafael, California 94901
Number of Employees2,849
Recent SEC Filing03/17/20234
Chairman & Chief Executive OfficerJean-Jacques Bienaimé
Chief Financial Officer & Executive VP-FinanceBrian R. Mueller
Chief Information OfficerEduardo E. von Pervieux
President-Worldwide Research & DevelopmentHenry J. Fuchs

Company Highlights

Price Open$90.01
Previous Close$90.11
52 Week Range$70.73 - 117.77
Market Capitalization$16.9 B
Shares Outstanding186.5 M
SectorHealth Technology
Next Earnings Announcement04/26/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings122.62
Earnings per Share$0.75
Beta vs. S&P 500N/A
Revenue$1.5 B
Net Profit Margin6.91%
Return on Equity3.13%

Analyst Ratings as of 03/17/2023

Consensus RecommendationConsensus Icon
Powered by Factset